If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

Share Price is delayed by 15 minutes
Get Live Data
748.00    -10.00 (-1.32%)
Bid:
747.50
Ask:
748.50
Spread: 1.00 (0.134%)
Market Cap: £2.52b
DRX Live PriceLast checked at - London Stock Exchange

Intraday Drax Share Chart

2022 Performance Awards - EPS Condition

19 Apr 2022 12:00

RNS Number : 5995I
Drax Group PLC
19 April 2022
 

19 April 2022

Drax Group plc

("Drax" or the "Group"; Symbol:DRX)

 

2022 Performance Awards - EPS Condition

At the time of publishing the annual report for the financial year ended 31 December 2021, Drax advised it would be separately determining, and thereafter releasing details of, the Cumulative Adjusted Earnings per Share performance condition which applies to grants made to PDMRs and other employees in the 2022 financial year.

The vesting of awards granted are subject to satisfying two performance criteria over the financial years 2022, 2023 and 2024. 50% of the awards will be measured based on Relative Total Shareholder Return relative to the FTSE-350, and the remaining 50% will be measured based on Cumulative Adjusted Earnings per Share.

Following a meeting of the Remuneration Committee, the proposed Cumulative Adjusted EPS target for 2022 has been agreed. The EPS target was set after considering the company's internal forecasts, market expectations and sector peers.

 

 

Threshold

Target

Maximum

239.5p

266.1p

292.7p

 

 

BASIS OF VESTING

Performance

Target

% of Award Vesting(of EPS performance condition)

Below threshold

0%

Threshold

239.5p

25%

Maximum

292.7p

100%

 

Vesting between the threshold and maximum will be on a straight-line basis.

The EPS target is 'Adjusted EPS', derived from Adjusted Results as reported in the Company's audited financial statements. Instances where such adjustments might apply include acquisition and restructuring costs, asset obsolescence charges and certain remeasurements on derivative contracts.

There may arise circumstances during the performance period where adjustment or discretion is applied by the Remuneration Committee by reference to exceptional items and the Remuneration Policy. The application of such adjustments would be considered during and upon completion of the performance cycle. In making their assessment, the Remuneration Committee will take into account appropriate advice (for example from our auditors, Remuneration Committee advisers or the Audit Committee) and also give due consideration to the shareholder experience. The Remuneration Committee would also take into account exceptional and unforeseen circumstances, including wider considerations such as the prevailing market environment, in assessing the appropriate level of vesting judged against the performance of the Company and management at the end of the performance period.

Total Shareholder Return relative to the FTSE-350 will be measured over the three-year period (2022-2024) consistent with the approach previously approved by shareholders.

The Remuneration Committee of Drax considers that attaining outturn at the top end of the range would represent strong performance considering the uncertain economic circumstances and the challenges to the broader economy. 

 

Ends

 

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com 

+44 (0) 7730 763 949

Brett Gladden, Group Company Secretarybrett.gladden@drax.com+44 (0)7936 362586

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFSUEESEEL
Date   Source Headline
5th Jan 20228:30 amRNSAdditional Listing
4th Jan 20223:49 pmRNSTotal Voting Rights
22nd Dec 20213:05 pmRNSDirector/PDMR Shareholding
15th Dec 20217:00 amRNSInvestment in BECCS FEED Study
14th Dec 20217:00 amRNSContracts to supply 2.8Mt of biomass
1st Dec 202112:19 pmRNSTotal Voting Rights
1st Dec 20217:02 amRNSCapital Markets Day - Update
1st Dec 20217:00 amRNSTrading Update
22nd Nov 20212:25 pmRNSNotice of Capital Markets Day
5th Nov 20218:30 amRNSAdditional Listing
1st Nov 20213:07 pmRNSTotal Voting Rights
21st Oct 20211:30 pmRNSAppointment of Non-Executive Directors
6th Oct 20218:00 amRNSBlock listing Interim Review - PSP
6th Oct 20218:00 amRNSBlock listing Interim Review - SAYE
6th Oct 20218:00 amRNSBlock listing Interim Review - DSP
4th Oct 202112:11 pmRNSTotal Voting Rights
27th Sep 20218:00 amRNSAdditional Listing
23rd Sep 202111:00 amRNSINTENTION TO CONDUCT AUDIT TENDER
19th Aug 20213:34 pmRNSDirector/PDMR Shareholding
9th Aug 202111:13 amRNSLTIP 2021 – EPS Performance Condition
2nd Aug 20211:12 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSHalf-year Report
22nd Jul 20217:40 amRNSNotice of Results
13th Jul 20217:00 amRNSRefinancing of Pinnacle Debt
8th Jul 20212:54 pmRNSHolding(s) in Company
1st Jul 202112:51 pmRNSTotal Voting Rights
1st Jul 202112:49 pmRNSHolding(s) in Company
1st Jul 20217:00 amRNSAcquisition of Joint Venture Interest
29th Jun 202110:38 amRNSHolding(s) in Company
15th Jun 20218:00 amRNSAdditional Listing
4th Jun 202111:19 amRNSHolding(s) in Company
4th Jun 202111:15 amRNSTotal Voting Rights
20th May 20218:00 amRNSHolding(s) in Company
5th May 202112:09 pmRNSHolding(s) in Company
5th May 20218:00 amRNSTotal Voting Rights
4th May 20219:30 amRNSNotice of Change to Director Details
29th Apr 202110:01 amRNSHolding(s) in Company
28th Apr 20218:00 amRNSAdditional Listing
23rd Apr 20213:12 pmRNSHolding(s) in Company
21st Apr 20212:00 pmRNSResult of AGM
21st Apr 20217:00 amRNSTrading Update
15th Apr 20219:29 amRNSHolding(s) in Company
13th Apr 20218:00 amRNSCompletion of acquisition
8th Apr 202110:08 amRNSHolding(s) in Company
7th Apr 20217:11 amRNSSatisfied conditions for proposed acquisition
1st Apr 20214:00 pmRNSBlock listing Interim Review - DSP
1st Apr 20213:58 pmRNSBlock listing Interim Review - PSP
1st Apr 20213:55 pmRNSBlock listing Interim Review - Sharesave
1st Apr 20212:10 pmRNSTotal Voting Rights
1st Apr 20212:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.